Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers
: To investigate whether the interactions of and with smoking are associated with the levels of P2Y12 receptor inhibition and CRP, in on-thienopyridine post-stenting patients. : At 1-month follow-up, the interactions of smoking and polymorphisms on the vasodilator-stimulated phosphoprotein - platele...
Gespeichert in:
| Veröffentlicht in: | Pharmacogenomics 2015-04, Vol.16 (5), p.459-469 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 469 |
|---|---|
| container_issue | 5 |
| container_start_page | 459 |
| container_title | Pharmacogenomics |
| container_volume | 16 |
| creator | Shahabi, Payman Cuisset, Thomas Stathopoulou, Maria G Morange, Pierre Emmanuel Grosdidier, Charlotte Herbeth, Bernard Siest, Gérard Alessi, Marie-Christine Visvikis-Siest, Sophie |
| description | : To investigate whether the interactions of
and
with smoking are associated with the levels of P2Y12 receptor inhibition and CRP, in on-thienopyridine post-stenting patients.
: At 1-month follow-up, the interactions of smoking and
polymorphisms on the vasodilator-stimulated phosphoprotein - platelet reactivity index (VASP PRI), and CRP were explored in three metabolizing groups (1128 patients) as follow: poor metabolizers (
carriers/
noncarriers); intermediate metabolizers (
carriers/
carriers or
noncarriers/
noncarriers); and ultrarapidmetabolizers (
allele noncarriers/
carriers). The interactions of metabolizing status and smoking was significant for CRP (p = 0.001) but not for VASP PRI (p = 0.734).
: Interaction between
polymorphisms and smoking modifies on-treatment CRP level of post-stenting, on-thienopyridine patients. This effect seems to be independent to the level of P2Y12 receptor inhibition.
Original submitted 1 August 2014; Revision submitted 4 February 2015 |
| doi_str_mv | 10.2217/pgs.15.17 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01708476v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A411315284</galeid><sourcerecordid>A411315284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-242b911f897c18a06fa23bb84ad3fe285387ccf9e096a68bab51eb142632bd403</originalsourceid><addsrcrecordid>eNqFkk2P0zAQhiMEYj_gwB9AkbjAocXjOLZzrFawi1SJC5wtx5m0XpK42M6u-u-Z0u4i0ErIB3vGz4zHr96ieANsyTmoj7tNWkK9BPWsOAclxEIzwZ_TWUi-4ALkWXGR0i1jHKRgL4szXjcga9DnxXiNE2bvyg4zxtFP2JVDuC8jpl2YEpY5lHnrcQq7ffQd3afSp9KmFJy3meh7n7fl1m-2GMu0TxlH6uanfrDjaLMPEwVlGsMPjOlV8aK3Q8LXp_2y-P7507erm8X66_WXq9V64URdZRqZtw1ArxvlQFsme8urttXCdlWPXNeVVs71DbJGWqlb29aALQguK952glWXxYdj360dzC760ca9Cdabm9XaHHIMFNNCyTsg9v2R3cXwc8aUzeiTw2GwE4Y5GdCCRFP06P9RqSQp2zBJ6Lt_0Nswx4k-_ZtipL6q_1AbO6Ah0UKO1h2ampUAqKDmWhC1fIKi1R20DhP2nvJ_FZy-72JIKWL_qAEwc3CMIccYqA0oYt-eBp3bEbtH8sEiBNRHoJ_zTLZwZAaH5hhRhXdkiica_wIsLszW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1676065175</pqid></control><display><type>article</type><title>Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers</title><source>MEDLINE</source><source>PubMed Central</source><creator>Shahabi, Payman ; Cuisset, Thomas ; Stathopoulou, Maria G ; Morange, Pierre Emmanuel ; Grosdidier, Charlotte ; Herbeth, Bernard ; Siest, Gérard ; Alessi, Marie-Christine ; Visvikis-Siest, Sophie</creator><creatorcontrib>Shahabi, Payman ; Cuisset, Thomas ; Stathopoulou, Maria G ; Morange, Pierre Emmanuel ; Grosdidier, Charlotte ; Herbeth, Bernard ; Siest, Gérard ; Alessi, Marie-Christine ; Visvikis-Siest, Sophie</creatorcontrib><description>: To investigate whether the interactions of
and
with smoking are associated with the levels of P2Y12 receptor inhibition and CRP, in on-thienopyridine post-stenting patients.
: At 1-month follow-up, the interactions of smoking and
polymorphisms on the vasodilator-stimulated phosphoprotein - platelet reactivity index (VASP PRI), and CRP were explored in three metabolizing groups (1128 patients) as follow: poor metabolizers (
carriers/
noncarriers); intermediate metabolizers (
carriers/
carriers or
noncarriers/
noncarriers); and ultrarapidmetabolizers (
allele noncarriers/
carriers). The interactions of metabolizing status and smoking was significant for CRP (p = 0.001) but not for VASP PRI (p = 0.734).
: Interaction between
polymorphisms and smoking modifies on-treatment CRP level of post-stenting, on-thienopyridine patients. This effect seems to be independent to the level of P2Y12 receptor inhibition.
Original submitted 1 August 2014; Revision submitted 4 February 2015</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs.15.17</identifier><identifier>PMID: 25916518</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Aged ; C-Reactive Protein - genetics ; clopidogrel ; CRP ; Cytochrome P-450 CYP2C19 - genetics ; cytochrome P450 ; Drug metabolism ; Drug therapy ; Female ; Genetic aspects ; Genetic polymorphisms ; Genetics ; Genotype ; Health aspects ; Heterozygote ; Human genetics ; Humans ; Inflammation - genetics ; Life Sciences ; Male ; Middle Aged ; Patient outcomes ; Phosphoproteins - metabolism ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; prasugrel ; Purinergic P2Y Receptor Antagonists - adverse effects ; Purinergic P2Y Receptor Antagonists - therapeutic use ; Smoking ; Smoking - genetics ; Stents ; Thienopyridines ; Thienopyridines - adverse effects ; Thienopyridines - therapeutic use ; Vasodilation - physiology</subject><ispartof>Pharmacogenomics, 2015-04, Vol.16 (5), p.459-469</ispartof><rights>COPYRIGHT 2015 Future Medicine Ltd.</rights><rights>2015 Future Medicine Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c453t-242b911f897c18a06fa23bb84ad3fe285387ccf9e096a68bab51eb142632bd403</cites><orcidid>0000-0001-8104-8425 ; 0000-0003-3927-5792</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25916518$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-01708476$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Shahabi, Payman</creatorcontrib><creatorcontrib>Cuisset, Thomas</creatorcontrib><creatorcontrib>Stathopoulou, Maria G</creatorcontrib><creatorcontrib>Morange, Pierre Emmanuel</creatorcontrib><creatorcontrib>Grosdidier, Charlotte</creatorcontrib><creatorcontrib>Herbeth, Bernard</creatorcontrib><creatorcontrib>Siest, Gérard</creatorcontrib><creatorcontrib>Alessi, Marie-Christine</creatorcontrib><creatorcontrib>Visvikis-Siest, Sophie</creatorcontrib><title>Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>: To investigate whether the interactions of
and
with smoking are associated with the levels of P2Y12 receptor inhibition and CRP, in on-thienopyridine post-stenting patients.
: At 1-month follow-up, the interactions of smoking and
polymorphisms on the vasodilator-stimulated phosphoprotein - platelet reactivity index (VASP PRI), and CRP were explored in three metabolizing groups (1128 patients) as follow: poor metabolizers (
carriers/
noncarriers); intermediate metabolizers (
carriers/
carriers or
noncarriers/
noncarriers); and ultrarapidmetabolizers (
allele noncarriers/
carriers). The interactions of metabolizing status and smoking was significant for CRP (p = 0.001) but not for VASP PRI (p = 0.734).
: Interaction between
polymorphisms and smoking modifies on-treatment CRP level of post-stenting, on-thienopyridine patients. This effect seems to be independent to the level of P2Y12 receptor inhibition.
Original submitted 1 August 2014; Revision submitted 4 February 2015</description><subject>Aged</subject><subject>C-Reactive Protein - genetics</subject><subject>clopidogrel</subject><subject>CRP</subject><subject>Cytochrome P-450 CYP2C19 - genetics</subject><subject>cytochrome P450</subject><subject>Drug metabolism</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Genetic aspects</subject><subject>Genetic polymorphisms</subject><subject>Genetics</subject><subject>Genotype</subject><subject>Health aspects</subject><subject>Heterozygote</subject><subject>Human genetics</subject><subject>Humans</subject><subject>Inflammation - genetics</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient outcomes</subject><subject>Phosphoproteins - metabolism</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>prasugrel</subject><subject>Purinergic P2Y Receptor Antagonists - adverse effects</subject><subject>Purinergic P2Y Receptor Antagonists - therapeutic use</subject><subject>Smoking</subject><subject>Smoking - genetics</subject><subject>Stents</subject><subject>Thienopyridines</subject><subject>Thienopyridines - adverse effects</subject><subject>Thienopyridines - therapeutic use</subject><subject>Vasodilation - physiology</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkk2P0zAQhiMEYj_gwB9AkbjAocXjOLZzrFawi1SJC5wtx5m0XpK42M6u-u-Z0u4i0ErIB3vGz4zHr96ieANsyTmoj7tNWkK9BPWsOAclxEIzwZ_TWUi-4ALkWXGR0i1jHKRgL4szXjcga9DnxXiNE2bvyg4zxtFP2JVDuC8jpl2YEpY5lHnrcQq7ffQd3afSp9KmFJy3meh7n7fl1m-2GMu0TxlH6uanfrDjaLMPEwVlGsMPjOlV8aK3Q8LXp_2y-P7507erm8X66_WXq9V64URdZRqZtw1ArxvlQFsme8urttXCdlWPXNeVVs71DbJGWqlb29aALQguK952glWXxYdj360dzC760ca9Cdabm9XaHHIMFNNCyTsg9v2R3cXwc8aUzeiTw2GwE4Y5GdCCRFP06P9RqSQp2zBJ6Lt_0Nswx4k-_ZtipL6q_1AbO6Ah0UKO1h2ampUAqKDmWhC1fIKi1R20DhP2nvJ_FZy-72JIKWL_qAEwc3CMIccYqA0oYt-eBp3bEbtH8sEiBNRHoJ_zTLZwZAaH5hhRhXdkiica_wIsLszW</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Shahabi, Payman</creator><creator>Cuisset, Thomas</creator><creator>Stathopoulou, Maria G</creator><creator>Morange, Pierre Emmanuel</creator><creator>Grosdidier, Charlotte</creator><creator>Herbeth, Bernard</creator><creator>Siest, Gérard</creator><creator>Alessi, Marie-Christine</creator><creator>Visvikis-Siest, Sophie</creator><general>Future Medicine Ltd</general><general>Future Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-8104-8425</orcidid><orcidid>https://orcid.org/0000-0003-3927-5792</orcidid></search><sort><creationdate>20150401</creationdate><title>Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers</title><author>Shahabi, Payman ; Cuisset, Thomas ; Stathopoulou, Maria G ; Morange, Pierre Emmanuel ; Grosdidier, Charlotte ; Herbeth, Bernard ; Siest, Gérard ; Alessi, Marie-Christine ; Visvikis-Siest, Sophie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-242b911f897c18a06fa23bb84ad3fe285387ccf9e096a68bab51eb142632bd403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>C-Reactive Protein - genetics</topic><topic>clopidogrel</topic><topic>CRP</topic><topic>Cytochrome P-450 CYP2C19 - genetics</topic><topic>cytochrome P450</topic><topic>Drug metabolism</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Genetic aspects</topic><topic>Genetic polymorphisms</topic><topic>Genetics</topic><topic>Genotype</topic><topic>Health aspects</topic><topic>Heterozygote</topic><topic>Human genetics</topic><topic>Humans</topic><topic>Inflammation - genetics</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient outcomes</topic><topic>Phosphoproteins - metabolism</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>prasugrel</topic><topic>Purinergic P2Y Receptor Antagonists - adverse effects</topic><topic>Purinergic P2Y Receptor Antagonists - therapeutic use</topic><topic>Smoking</topic><topic>Smoking - genetics</topic><topic>Stents</topic><topic>Thienopyridines</topic><topic>Thienopyridines - adverse effects</topic><topic>Thienopyridines - therapeutic use</topic><topic>Vasodilation - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shahabi, Payman</creatorcontrib><creatorcontrib>Cuisset, Thomas</creatorcontrib><creatorcontrib>Stathopoulou, Maria G</creatorcontrib><creatorcontrib>Morange, Pierre Emmanuel</creatorcontrib><creatorcontrib>Grosdidier, Charlotte</creatorcontrib><creatorcontrib>Herbeth, Bernard</creatorcontrib><creatorcontrib>Siest, Gérard</creatorcontrib><creatorcontrib>Alessi, Marie-Christine</creatorcontrib><creatorcontrib>Visvikis-Siest, Sophie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shahabi, Payman</au><au>Cuisset, Thomas</au><au>Stathopoulou, Maria G</au><au>Morange, Pierre Emmanuel</au><au>Grosdidier, Charlotte</au><au>Herbeth, Bernard</au><au>Siest, Gérard</au><au>Alessi, Marie-Christine</au><au>Visvikis-Siest, Sophie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>16</volume><issue>5</issue><spage>459</spage><epage>469</epage><pages>459-469</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>: To investigate whether the interactions of
and
with smoking are associated with the levels of P2Y12 receptor inhibition and CRP, in on-thienopyridine post-stenting patients.
: At 1-month follow-up, the interactions of smoking and
polymorphisms on the vasodilator-stimulated phosphoprotein - platelet reactivity index (VASP PRI), and CRP were explored in three metabolizing groups (1128 patients) as follow: poor metabolizers (
carriers/
noncarriers); intermediate metabolizers (
carriers/
carriers or
noncarriers/
noncarriers); and ultrarapidmetabolizers (
allele noncarriers/
carriers). The interactions of metabolizing status and smoking was significant for CRP (p = 0.001) but not for VASP PRI (p = 0.734).
: Interaction between
polymorphisms and smoking modifies on-treatment CRP level of post-stenting, on-thienopyridine patients. This effect seems to be independent to the level of P2Y12 receptor inhibition.
Original submitted 1 August 2014; Revision submitted 4 February 2015</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>25916518</pmid><doi>10.2217/pgs.15.17</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8104-8425</orcidid><orcidid>https://orcid.org/0000-0003-3927-5792</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-2416 |
| ispartof | Pharmacogenomics, 2015-04, Vol.16 (5), p.459-469 |
| issn | 1462-2416 1744-8042 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01708476v1 |
| source | MEDLINE; PubMed Central |
| subjects | Aged C-Reactive Protein - genetics clopidogrel CRP Cytochrome P-450 CYP2C19 - genetics cytochrome P450 Drug metabolism Drug therapy Female Genetic aspects Genetic polymorphisms Genetics Genotype Health aspects Heterozygote Human genetics Humans Inflammation - genetics Life Sciences Male Middle Aged Patient outcomes Phosphoproteins - metabolism Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use prasugrel Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Smoking Smoking - genetics Stents Thienopyridines Thienopyridines - adverse effects Thienopyridines - therapeutic use Vasodilation - physiology |
| title | Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A55%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20determined%20low%20response%20to%20thienopyridines%20is%20associated%20with%20higher%20systemic%20inflammation%20in%20smokers&rft.jtitle=Pharmacogenomics&rft.au=Shahabi,%20Payman&rft.date=2015-04-01&rft.volume=16&rft.issue=5&rft.spage=459&rft.epage=469&rft.pages=459-469&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs.15.17&rft_dat=%3Cgale_hal_p%3EA411315284%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1676065175&rft_id=info:pmid/25916518&rft_galeid=A411315284&rfr_iscdi=true |